Mykronor (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Mykronor, is a sympathomimetic presented as an injectable solution for intravenous use. It acts as a potent vasopressor to raise blood pressure in patients experiencing severe hypotension, including those in septic or cardiogenic shock. The drug rapidly stimulates alpha‑adrenergic receptors, producing vasoconstriction and improving organ perfusion during critical care.

GNH USA supplies Mykronor as a licensed, GDP‑compliant international pharmaceutical product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Mykronor is used as a vasopressor in critical care settings to manage low blood pressure and shock states. - Hypotension: restores arterial pressure and improves tissue perfusion in patients with acute drops in blood pressure. - Septic shock: counteracts vasodilatory failure by increasing systemic vascular resistance, supporting hemodynamic stability. - Cardiogenic shock: augments preload and afterload to sustain cardiac output during severe heart failure.

Noradrenaline tartrate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache occurring during infusion. - Tachycardia: increased heart rate as a reflex response to vasoconstriction. - Palpitations: sensation of irregular or forceful heartbeats. - Nausea: transient nausea reported in some patients. - Peripheral ischemia: reduced blood flow to extremities causing coldness or discoloration.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced coronary blood flow leading to chest pain. - Severe hypertension: abrupt, uncontrolled rise in blood pressure. - Tissue necrosis: local tissue death at extravasation sites. - Pulmonary edema: fluid accumulation in lungs due to increased afterload.

When using Mykronor, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Dose titration: adjust infusion rate based on continuous blood pressure monitoring. - Cardiac monitoring: observe for arrhythmias and ischemic changes during therapy. - Extravasation risk: avoid infiltration; stop infusion immediately if leakage is suspected. - Fluid balance: assess volume status to prevent overload or depletion. - Concomitant vasopressors: evaluate cumulative pressor effect when combined with other agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline tartrate can interact with other medications, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may blunt compensatory tachycardia and exacerbate hypotension. - MAO inhibitors: increase risk of hypertensive crisis when combined with sympathomimetics. - Tricyclic antidepressants: potentiate vasoconstrictive effects, raising blood pressure excessively.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance vasodilatory opposition, requiring dose adjustments. - Diuretics: alter intravascular volume, affecting pressor response. - Sedatives/anxiolytics: can mask signs of excessive vasoconstriction or hypertension.